Safety, tolerability, and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers
Ongoing Monitoring: The 12-Week and 24-Week Panels After clearing the 4-week gate, patients on stable doses transition to monitoring every 8 to 12 weeks
Ma, G., Zheng, Q., Xu, M., Zhou, X., Lu, L., Li, Z., & Zheng, G
A.GonzalezF
Benefits Observed Faster muscle and tendon recovery Reduced joint inflammation Improved gut health and tissue protection Enhanced blood flow to injured areas TB-500: The Repair Accelerator TB-500 (Thymosin Beta-4) is another naturally occurring peptide involved in cellular regeneration
Contraindications: Known allergy or hypersensitivity to NAD+ or its components